Kirsty LEE – Page 4 – Medical News Asia

About Kirsty LEE

This author has not written his bio yet.
But we are proud to say that Kirsty LEE contributed 45 entries already.

Entries by Kirsty LEE

Selpercatinib displays efficacy in RET fusion-positive non-small cell lung cancer

7 September 2020/0 Comments/in US FDA Onc\Haem Approvals, Lung Cancer, Oncology, Chemotherapy, Targeted Therapies/by Kirsty LEE

Aberrant RET activation has shown to be a clinical driver of tumour growth and proliferation. It is reported that 1-2% of non-small cell lung cancer patients have activating RET fusions. Clinical characteristics of these patients are generally younger (<60 years) with minimal or no smoking history, and frequent presentation with brain metastases at diagnosis of advanced disease. RET mutations are mutually exclusive with other common lung cancer genetic abberations, such as reported for KRAS, EGFR, and ALK.

First liquid biopsy for NSCLC to receive FDA approval

7 September 2020/0 Comments/in Breast Cancer, Gastrointestinal Cancer, Genitourinary Cancer, US FDA Onc\Haem Approvals, Gynaecological Cancer, Lung Cancer, Oncology, Targeted Therapies/by Kirsty LEE

The development of new targeted therapies for non-small cell lung cancer (NSCLC) in recent years has changed the standard of care for the later stages of NSCLC in specific population groups.

ESMO releases the first guideline on NGS testing in cancers

7 September 2020/0 Comments/in Breast Cancer, Gastrointestinal Cancer, Genitourinary Cancer, Gynaecological Cancer, Lung Cancer, Oncology, Targeted Therapies, Pathology/by Kirsty LEE

Precision therapies were first approved for cancer in 1998, when trastuzumab was approved for HER2+ breast cancer, opening the door for other targeted therapies such as imatinib for Philadelphia chromosome-positive chronic myelogenous leukaemia.

Risk of thrombosis with SARS-CoV-2 infection

27 August 2020/in COVID-19, Therapeutic Areas, Critical Care Medicine, SARS-CoV2, Cardiovascular, Infectious Disease/by Kirsty LEE

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2/2019-nCoV) in late 2019 has led to a global pandemic.

Class effect of SGLT2 inhibitors on heart failure reduction solidified with dapagliflozin and empagliflozin results

25 August 2020/0 Comments/in Cardiovascular/by Kirsty LEE

Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been used in the treatment of type 2 diabetes mellitus (T2DM) to inhibit renal glucose reabsorption and thereby increase urinary glucose loss.

No difference in kidney transplantation outcomes for HIV-positive recipients regardless of donor HIV status

25 August 2020/0 Comments/in Organ Transplant, HIV, Infectious Disease, Specialty Care/by Kirsty LEE

Human immunodeficiency virus (HIV) has been transformed into a chronic disease to the successful introduction of antiretroviral therapy (ART), and people living with HIV (PWH) now experience morbidity from other chronic conditions, such as kidney, liver, and heart disease.

Residual risk of hepatocellular carcinoma in older Hepatitis C patients even after viral clearance

13 August 2020/0 Comments/in Gastrointestinal Cancer, Infectious Disease, Hepatitis C Virus, Oncology/by Kirsty LEE

Infection with the hepatitis C virus (HCV) can lead to chronic hepatitis C infection (CHC) and liver complications such as fibrosis, hepatocellular carcinoma (HCC), cirrhosis, and end-stage liver disease.

Potential protective effects of the influenza vaccine on cardiovascular outcomes in high-risk populations

13 August 2020/0 Comments/in Cardiovascular, Influenza, Infectious Disease/by Kirsty LEE

Influenza A and B viruses are the cause of 3 to 5 million infection, and 250,000 to 500,00 deaths each year worldwide. Particular groups of the population are at higher risk of infection, including the elderly, immunocompromised, and infants.

Updated human papillomavirus vaccination and testing recommendations from the American Cancer Society

13 August 2020/0 Comments/in Gynaecological Cancer, Head and Neck Cancer, Infectious Disease, Human Papillomavirus, Oncology, Vaccines/by Kirsty LEE

Human papillomavirus (HPV) is one of the most common causes of sexually transmitted disease worldwide. HPV is associated with a variety of clinical conditions that can range from cutaneous warts to cervical or anal cancer. Cervical cancer is the third most common cancer in women in the United States, and may constitute up to 25% of all female cancers in developing countries.

Interim results of a Phase 2b/3 trial investigating a long-acting injectable of cabotegravir for pre-exposure prophylaxis of HIV

4 August 2020/Enter your password to view comments./in AIDS, HIV, Infectious Disease/by Kirsty LEE

There is no excerpt because this is a protected post.